UAB Comprehensive Cancer Center’s Patient Care Connect Program received a distinguished Innovator Award from the Association of Community Cancer Centers for providing stellar cancer care with cost savings.
UAB is the only institution in Alabama chosen to date to participate in the TAPUR Study to help further understand targeted therapies in patients with advanced cancers.
Recent findings from an innovative nationwide trial indicate that the drug pembrolizumab, when used in combination with standard therapy, may provide positive results for patients with locally advanced breast cancer.
UAB is an Equal Employment/Equal Educational Opportunity Institution dedicated to providing equal opportunities and equal access to all individuals regardless of race, color, religion, ethnic or national origin, sex (including pregnancy), genetic information, age, disability, religion, sexual orientation, gender identity, gender expression, and veteran’s status. As required by Title IX, UAB prohibits sex discrimination in any education program or activity that it operates. Individuals may report concerns or questions to UAB’s Assistant Vice President and Senior Title IX Coordinator. The Title IX notice of nondiscrimination is located at uab.edu/titleix.